recent
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
zika
viru
outbreak
exemplifi
continu
threat
emerg
virus
human
health
inabl
rapidli
develop
effect
therapeut
countermeasur
mani
virus
includ
merscov
crimeancongo
hemorrhag
fever
viru
cchfv
encod
deubiquitin
dub
enzym
critic
viral
replic
pathogen
bind
remov
ubiquitin
ub
interferon
stimul
gene
cellular
protein
suppress
host
antivir
innat
immun
respons
varieti
viral
dub
vdub
includ
merscov
papainlik
proteas
respons
cleav
viral
replicas
polyprotein
replic
therebi
critic
compon
viral
replic
cycl
togeth
make
vdub
highli
attract
antivir
drug
target
howev
structur
similar
catalyt
core
vdub
human
dub
complic
develop
select
small
molecul
vdub
inhibitor
thu
develop
altern
strategi
target
vdub
activ
ration
protein
design
approach
report
use
phagedisplay
ubiquitin
variant
ubv
librari
rapidli
identifi
potent
highli
select
proteinbas
inhibitor
target
dub
domain
merscov
cchfv
ubv
bound
vdub
high
affin
specif
inhibit
deubiquitin
deisgyl
case
merscov
also
viral
replic
polyprotein
process
cocrystal
studi
reveal
critic
molecular
interact
ubv
merscov
cchfv
vdub
account
observ
bind
specif
high
affin
final
express
ubv
merscov
infect
reduc
infecti
progeni
titer
four
order
magnitud
demonstr
remark
potenc
ubv
antivir
agent
result
therebi
establish
strategi
produc
proteinbas
inhibitor
could
protect
divers
rang
virus
provid
ubv
via
mrna
protein
deliveri
technolog
transgen
techniqu
emerg
virus
pose
tremend
challeng
human
health
vaccinebas
approach
desir
term
infect
prevent
longer
term
altern
antivir
strategi
need
especi
provid
treatment
option
infect
patient
acut
outbreak
appli
protein
engin
technolog
target
virusencod
deubiquitin
enzym
two
virus
signific
impact
human
health
middl
east
respiratori
syndrom
coronaviru
merscov
crimeancongo
hemorrhag
fever
viru
cchfv
result
rapid
identif
ubiquitin
variant
ubv
inhibitor
bound
high
affin
specif
viral
deubiquitin
enzym
protein
inhibit
catalyt
activ
deubiquitin
enzym
almost
complet
block
merscov
infect
work
provid
proofofprincipl
structur
divers
virusspecif
deubiquitin
enzym
select
target
ration
protein
design
technolog
therefor
open
new
avenu
quickli
develop
molecularli
tailor
therapi
across
broad
spectrum
viral
pathogen
infect
human
livestock
plant
rapid
develop
antivir
agent
plo
pathogen
http
doi
ubiquitin
posttransl
modif
mediat
enzym
cascad
result
conjug
ubiquitin
ub
cellular
protein
process
regul
part
activ
cellular
deubiquitin
enzym
dub
remov
ub
cellular
protein
given
essenti
role
ub
system
regul
larg
number
critic
cellular
process
surpris
virus
acquir
mean
modul
system
order
promot
infect
replic
host
cell
particular
virusencod
dub
revers
ubiquitin
process
alter
host
signal
pathway
critic
induct
cellular
antivir
proinflammatori
innat
immun
respons
addit
remov
ub
molecul
host
protein
mani
viral
dub
vdub
also
remov
ublik
protein
interferonstimul
gene
suppress
antivir
respons
importantli
number
vdub
also
play
essenti
role
viral
replic
togeth
replic
andor
deubiquitin
activ
viral
proteas
contribut
directli
pathogenesi
viral
infect
vivo
make
ideal
antivir
drug
target
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
virus
caus
signific
concern
global
due
rapid
emerg
high
lethal
rate
human
high
potenti
genet
recombin
coronavirus
initi
express
nonstructur
protein
nsp
larg
viral
polyprotein
process
function
domain
proteas
encod
within
polyprotein
establish
viral
replicationtranscriptas
complex
sarsand
merscov
releas
activ
papainlik
proteas
pl
pro
domain
situat
within
process
indispens
replic
chymotrypsinlik
proteas
pro
correspond
respons
cleav
remain
part
polyprotein
releas
matur
nsp
strikingli
coronavir
pl
pro
also
act
vdub
suppress
host
antivir
innat
immun
respons
target
cellular
ubconjug
substrat
cov
proteas
wellrecogn
drug
target
sinc
emerg
zoonot
cov
research
focus
identif
develop
small
molecul
inhibitor
target
enzym
anoth
highli
pathogen
viru
encod
vdub
nairoviru
crimeancongo
hemorrhag
fever
viru
cchfv
cchfv
vdub
domain
locat
within
larg
l
segment
genom
also
explicitli
implic
evas
host
uband
innat
immun
respons
crystal
structur
pl
pro
mersand
sarscov
reveal
proteas
share
structur
similar
cellular
dub
belong
ubiquitinspecif
proteas
usp
famili
convers
structur
studi
nairoviru
vdub
reveal
resembl
ovarian
tumor
otu
domain
famili
dub
addit
well
character
vdub
conserv
coronaviru
nairoviru
famili
respect
numer
vdub
identifi
across
divers
distantli
relat
viru
lineag
signific
concern
human
health
agricultur
includ
arterivirus
herpesvirus
adenovirus
picornavirus
hepadnavirus
tymovirus
emphas
broad
potenti
util
vdubspecif
antivir
import
vdub
viral
replic
innat
immun
evas
make
attract
pharmacolog
target
although
structur
similar
human
dub
pose
signific
challeng
complic
success
develop
highli
select
small
molecul
vdub
inhibitor
despit
intens
effort
hand
inhibitor
target
vdub
proteas
report
none
approv
clinic
use
meet
challeng
develop
strategi
target
vdub
activ
antivir
approach
rapid
identif
virusspecif
proteinbas
vdub
inhibitor
phagedisplay
librari
billion
ub
variant
ubv
exquisit
specif
identifi
ubv
also
enabl
us
isol
ubv
potent
inhibit
human
ubbind
protein
equal
high
specif
describ
ubv
select
block
deubiquitin
deisgyl
activ
merscov
cchfv
otu
vdub
domain
importantli
ubv
specif
merscov
abolish
replic
polyprotein
process
activ
express
merscovspecif
ubv
merscov
infect
reduc
infecti
progeni
titer
four
order
magnitud
demonstr
remark
potenc
ubv
antivir
agent
ubv
librari
screen
merscov
pl
pro
domain
merscov
pl
pro
cchfv
otu
domain
cchfv
otu
within
three
week
ubv
identifi
bound
high
affin
either
merscov
pl
pro
cchfv
otu
fig
confirm
specif
ubv
toward
cognat
vdub
phagedisplay
ubv
challeng
divers
panel
dub
sever
speci
repres
distinct
dub
famili
usp
otu
ubiquitin
ctermin
hydrolas
uch
ubv
bound
cognat
viral
protein
addit
dub
fig
determin
bind
affin
ubv
phage
enzymelink
immunosorb
assay
fig
biolay
interferometri
bli
measur
perform
tabl
ubv
found
bind
cognat
vdub
affin
low
subnanomolar
rang
wherea
wildtyp
ub
ubwt
show
bind
merscov
cchfv
vdub
high
micromolar
rang
fig
tabl
consist
high
affin
observ
ubv
toward
respect
vdub
ubv
also
potent
inhibit
deubiquitin
deisgyl
activ
merscov
pl
pro
cchfv
otu
measur
use
fluorogen
substrat
ubamc
respect
fig
fig
potent
inhibitor
merscov
pl
pro
cchfv
otu
deubiquitin
ic
nm
deisglyat
ic
nm
deubiquitin
ic
nm
deisglyat
ic
nm
respect
tabl
furthermor
ubv
confirm
inhibit
process
tetraub
substrat
respect
vdub
fig
reveal
molecular
basi
inhibit
merscov
pl
pro
ubv
crystal
structur
enzym
determin
bound
fig
tabl
ubv
bound
nearli
ident
orient
ubwt
fig
fig
interfac
surfac
area
substitut
common
posit
fig
found
promot
favor
hydrophob
interact
enzym
rel
ubwt
comparison
ubwt
residu
val
ubv
residu
ile
extend
hydrophob
pocket
pl
pro
form
residu
thr
val
asterisk
denot
amino
acid
number
merscov
polyprotein
fig
ubv
residu
phe
insert
hydrophob
pocket
form
pl
pro
residu
trp
glu
val
leu
tyr
tyr
form
interact
arg
fig
extens
interact
form
pl
pro
ubwt
interfac
ubwt
residu
ala
addit
ubv
residu
tyr
make
extens
hydrophob
interact
val
gli
compar
ubwt
residu
glu
fig
ubv
also
differ
ctermin
residu
posit
fig
asn
extend
activ
site
form
hydrogen
bond
network
asp
gli
fig
mimic
hydrogen
bond
form
region
merscov
pl
pro
ubwt
residu
arg
gli
gli
fig
pro
form
analog
hydrogen
bond
network
like
contribut
decreas
inhibitori
potenc
compar
fig
fig
instead
pro
ctermin
tail
exclud
activ
site
mainchain
interact
hydrogen
bond
form
mainchain
amid
nitrogen
arg
backbon
carbonyl
glu
fig
structur
comparison
ctermin
region
near
pl
pro
activ
site
shown
fig
addit
substitut
ntermin
region
fig
region
make
favour
contact
merscov
pl
pro
fact
residu
respect
fail
resolv
electron
densiti
map
fig
taken
togeth
structur
analys
reveal
small
subset
substitut
suffici
enhanc
hydrophob
pack
hydrogen
bond
network
endow
highli
potent
specif
inhibitori
activ
merscov
pl
pro
similarli
crystal
structur
cchfv
otu
determin
bound
gain
insight
select
block
dub
deisgyl
activ
viral
proteas
fig
tabl
bound
orient
ubwt
similar
buri
surfac
area
fig
fig
interestingli
substitut
ubv
concentr
ctermin
region
fig
substitut
posit
downstream
found
interact
enzym
ubv
tyr
improv
hydrophob
pack
thr
val
val
asterisk
bind
specif
phagedisplay
ubv
yaxi
shown
across
group
dub
xaxi
assess
phage
elisa
subsatur
concentr
phage
ad
immobil
protein
indic
bound
phage
detect
addit
colorimetr
develop
tmb
peroxidas
substrat
mean
valu
absorb
nm
shade
blackredyellow
gradient
c
inhibit
merscov
pl
pro
solid
line
cchfv
otu
dash
line
cognat
ubv
shown
doserespons
curv
use
ubamc
left
right
substrat
ic
valu
determin
concentr
ubv
reduc
proteolyt
activ
tabl
ubwt
data
obtain
deisgyl
assay
fit
graphpad
prism
line
shown
effect
ubv
inhibitor
vdub
activ
tetraub
substrat
purifi
merscov
pl
pro
top
panel
cchfv
otu
bottom
panel
incub
indic
ubv
ubwt
neg
control
biotinyl
tetraub
time
cours
minut
western
blot
probe
extravidinhrp
eahrp
detect
biotinub
inhibit
proteolysi
shown
delay
appear
digest
product
triub
diub
monoub
denot
amino
acid
number
larg
segmentencod
protein
cchfv
rel
ubwt
fig
residu
leu
project
hydrophob
caviti
cchfv
otu
form
residu
val
ile
val
ile
equival
ub
wt
residu
val
fig
conform
freedom
gli
substitut
posit
enabl
ctermin
tail
ubv
form
numer
favor
interact
enzym
residu
gli
val
respect
occupi
space
cchfv
otu
surfac
case
ubwt
occupi
sidechain
arg
fig
altern
conform
permit
gli
allow
sidechain
trp
trp
respect
pack
within
differ
adjac
groov
near
cchfv
otu
activ
site
trp
form
interact
arg
fig
amid
nitrogen
group
residu
trp
form
hydrogen
bond
side
chain
gln
fig
convers
trp
interact
cchfv
otu
instead
pack
hydrophob
caviti
within
ubv
fig
differ
orient
ctermin
tail
aris
variat
posit
residu
val
pack
cchfv
otu
residu
trp
pro
appear
restrict
conform
freedom
enabl
hydrophob
interact
trp
thr
fig
togeth
pack
orient
trp
addit
contact
like
account
high
bind
affin
cchfv
otu
tabl
explor
effect
ubv
merscov
pl
pro
activ
cell
deubiquitin
assay
perform
transfect
cell
combin
plasmid
encod
follow
protein
hatag
ub
becom
conjug
cellular
protein
merscov
pl
pro
ubv
unconjugat
due
substitut
ctermin
digli
motif
clear
decreas
cellular
haub
conjug
observ
coexpress
merscov
pl
pro
effect
upon
express
catalyt
inact
mutant
fig
compar
lane
coexpress
increas
dose
differ
ubv
attenu
merscov
pl
pro
dub
activ
vari
degre
fig
fig
dosedepend
manner
coexpress
result
sever
inhibit
haub
deconjug
mediat
merscov
pl
pro
wherea
coexpress
unconjugat
form
ubwt
neg
control
ubaa
contain
substitut
effect
dub
activ
merscov
pl
pro
dose
fig
compar
lane
like
strong
effect
result
near
complet
inhibit
merscov
pl
pro
dub
activ
lowest
ubv
dose
wherea
inhibitori
effect
appar
higher
ubv
dose
fig
notabl
none
ubv
inhibit
dub
activ
close
relat
sarscov
pl
pro
highlight
specif
merscov
pl
pro
fig
superposit
onto
ub
domain
previous
determin
sarscovub
complex
suggest
phe
ile
clash
val
met
sarscov
pl
pro
respect
offer
plausibl
explan
specif
toward
merscov
pl
pro
fig
previous
found
dub
activ
merscov
pl
pro
suppress
promot
activ
upon
activ
cellular
innat
immun
signal
luciferasebas
report
assay
show
ectop
express
ubv
compet
endogen
ub
result
repres
least
three
independ
experi
signific
rel
wildtyp
without
express
ubv
calcul
use
unpair
twotail
student
bind
merscov
pl
pro
result
allevi
suppress
promot
activ
fig
fig
consist
describ
bind
inhibit
data
potent
block
abil
merscov
pl
pro
suppress
promot
activ
wherea
none
ubv
abl
block
suppress
promot
activ
sarscov
pl
pro
fig
ubv
thu
prevent
merscov
pl
pro
mediat
suppress
cellular
antivir
innat
immun
respons
remark
select
virusspecif
manner
critic
step
replic
cycl
merscov
process
viral
polyprotein
function
nonstructur
protein
nsp
accomplish
part
proteas
activ
pl
pro
cleav
junction
order
assess
abil
ubv
inhibit
merscov
pl
pro
mediat
polyprotein
process
activ
tran
cleavag
assay
perform
flagtag
ubv
merscov
pl
pro
coexpress
ntermin
hatag
ctermin
fragment
viral
polyprotein
encompass
ctermin
part
exclud
pl
pro
domain
tran
cleavag
junction
indic
proteolyt
activ
pl
pro
infect
merscov
pl
pro
effici
cleav
product
wherea
activ
site
mutant
fig
compar
lane
cleavag
site
affect
upon
express
neg
control
ubaa
wherea
fraction
cleav
upon
express
lowest
dose
cleavag
complet
block
higher
ubv
dose
fig
compar
lane
fig
increas
dose
also
result
reduc
cleavag
gradual
precursor
observ
fig
directli
ass
abil
ubv
inhibit
merscov
replic
merscov
pl
pro
specif
ubv
ectop
express
cell
cultur
cell
subsequ
infect
merscov
cell
line
transduc
lentivirus
encod
flagtag
ubv
ubaa
gfp
effici
express
gfp
cell
confirm
fluoresc
microscopi
western
blot
fig
either
hour
posttransduct
cell
infect
merscov
multipl
infect
merscov
titer
determin
supernat
harvest
hour
post
infect
fig
cell
express
result
significantli
lower
viru
titer
drop
x
plaqu
form
unit
pfu
ml
recov
control
cell
pfuml
respect
merscov
infect
start
hour
posttransduct
fig
effect
ubv
even
pronounc
cell
infect
merscov
hour
posttransduct
viru
titer
drop
pfuml
upon
express
repres
reduct
infecti
progeni
titer
four
order
magnitud
fig
correl
higher
express
test
signific
valu
indic
p
bar
repres
mean
error
bar
repres
sd
c
proteolyt
cleavag
capabl
merscov
pl
pro
assess
presenc
ubv
ntermin
hatag
ctermin
exclud
pl
pro
domain
coexpress
merscov
pl
pro
wild
type
activ
site
mutant
c
flagmeubv
increas
dose
gfp
transfect
control
cell
lyse
hour
post
transfect
proteolyt
cleavag
activ
assess
western
blot
detect
gener
ntermin
hatag
ctermin
cleavag
product
merscov
titer
collect
supernat
lentiviru
transduc
subsequ
merscov
infect
cell
cell
transduc
lentivirus
encod
flagubv
flagubaa
gfp
latter
two
control
either
hour
hour
posttransduct
cell
infect
merscov
multipl
infect
anoth
hour
cultur
supernat
harvest
merscov
titer
determin
plaqu
assay
vero
cell
signific
differ
rel
merscov
titer
lentiviru
transduc
cell
express
ubaa
indic
p
bar
repres
mean
error
bar
repres
sd
ubv
time
point
fig
fig
cell
express
gfp
ubaa
affect
merscov
titer
compar
nontransduc
cell
wherea
express
led
two
order
magnitud
reduct
viru
titer
even
greater
reduct
three
order
magnitud
observ
upon
express
fig
effect
ubv
merscov
progeni
titer
sever
cell
compar
cell
might
due
gener
higher
express
ubv
cell
cell
fig
fig
fig
taken
togeth
studi
show
ubv
readili
inhibit
proteolyt
activ
merscov
pl
pro
cell
provid
extrem
effect
protect
merscov
infect
continu
introduct
virus
zoonot
sourc
human
popul
pose
seriou
constant
threat
human
health
case
coronaviru
infect
therapeut
option
limit
vaccin
develop
remain
progress
describ
uniqu
protein
engin
platform
use
rapidli
gener
ubv
select
block
activ
vdub
rang
evolutionarili
distinct
viral
lineag
inde
ubv
gener
merscov
almost
complet
abolish
replic
viru
host
cell
meanwhil
none
ubv
gener
studi
like
crossreact
human
dub
toxic
observ
upon
express
ubv
demonstr
potenti
therapeut
safeti
target
intracellular
target
proteinbas
inhibitor
current
therapeut
option
due
practic
limit
immunogen
lack
effici
mean
deliv
protein
cell
vivo
howev
progress
continu
made
method
intracellular
deliveri
mrna
protein
strategi
reduc
immunogen
includ
use
mirrorimag
protein
develop
thu
futur
hope
ubv
may
becom
bona
fide
drug
candid
present
best
view
tool
compound
enabl
drug
discoveri
exampl
interfac
ubv
vdub
larg
recent
use
combinatori
mutagenesi
reveal
smaller
site
human
usp
within
ubv
interact
interfac
may
amen
target
smallmolecul
inhibitor
design
inde
design
small
molecul
target
proteinprotein
interfac
remain
challeng
success
exampl
polypeptidebas
tool
facilit
design
screen
small
molecul
inhibitor
plethora
virus
caus
human
diseas
encod
vdub
implic
replic
andor
pathogenesi
emphas
potenti
clinic
import
vdub
therapeut
target
ubv
develop
platform
also
readili
extend
target
virus
infect
plant
anim
econom
import
includ
porcin
reproduct
respiratori
syndrom
viru
equin
arter
viru
bovin
coronaviru
transmiss
gastroenter
viru
porcin
epidem
diarrhea
viru
turnip
yellow
mosaic
viru
encod
vdub
essenti
viru
replic
contrast
vdub
like
cchfv
otu
proteas
appear
process
viral
polyprotein
instead
dedic
increas
viral
pathogen
suppress
cellular
innat
immun
interestingli
cchfv
otu
proteas
compris
domain
viral
polymeras
target
ubv
may
suppress
viral
pathogen
rna
replic
well
sinc
found
viral
otu
dub
activ
suppress
proteasomedepend
viral
polymeras
degrad
addit
strong
bind
ubv
viral
polymeras
could
caus
steric
hindranc
way
affect
polymeras
function
current
transgen
technolog
livestock
plant
crop
express
virusspecif
ubv
could
readili
engin
gener
virusresist
organ
signific
progress
also
made
toward
develop
anim
model
merscov
infect
review
includ
mous
model
use
concert
mouseadapt
merscov
strain
togeth
mimick
merscov
patholog
observ
human
technolog
provid
attract
platform
assess
efficaci
ubv
deliveri
system
treat
merscov
infect
vivo
util
ub
scaffold
templat
vdub
inhibitor
develop
exploit
larg
ubbind
interfac
provid
high
degre
specif
comparison
small
moleculebas
approach
sinc
latter
usual
reli
target
activ
site
viral
proteas
therebi
invok
risk
crossreact
cellular
proteas
amino
acid
substitut
ubv
confer
potent
inhibit
vdub
distribut
across
rel
larg
bind
interfac
specul
resist
ubv
less
like
develop
comparison
smallmolecul
inhibitor
larger
bind
surfac
much
tighter
bind
affin
ubv
low
subnanomolar
fig
compar
report
micromolar
affin
smallmolecul
inhibitor
merscov
pl
pro
impli
rather
extens
mutat
viral
proteas
necessari
effici
repel
ubv
sinc
develop
resist
mutat
requir
viru
replic
extrem
reduct
merscov
progeni
titer
upon
express
ubv
infect
therefor
expect
sever
delay
occurr
resist
addit
resist
viru
happen
alreadi
present
quasi
speci
like
mutat
repel
ubv
vdub
concomitantli
lead
less
optim
bind
viral
proteas
mayb
even
viru
replicas
polyprotein
therefor
resist
viru
expect
attenu
least
reduc
deubiquitinatingdeisgyl
activ
import
viru
capac
suppress
host
innat
immun
respons
idea
support
describ
escap
mutant
mhv
broadspectrum
cov
proteas
inhibitor
inhibitorresist
viru
attenu
mice
highlight
mutant
gener
cost
replic
fit
futur
experi
experiment
assess
develop
ubv
resist
infect
cell
cultur
mous
model
show
whether
specul
correct
ultim
event
resist
strain
emerg
clinic
set
new
ubv
target
strain
also
gener
rapidli
importantli
unlik
smallmolecul
approach
take
year
implement
often
fail
phage
display
yield
potent
select
viral
inhibitor
week
rate
could
allow
therapeut
develop
keep
pace
continu
emerg
pathogen
virus
limit
pandem
potenti
togeth
find
make
explor
ubv
potent
rapidli
develop
antivir
agent
excit
promis
ventur
phagedisplay
ubv
librari
use
studi
reamplifi
librari
previous
describ
protein
immobil
follow
ubv
select
done
accord
establish
protocol
briefli
purifi
viral
proteas
coat
maxisorp
plate
thermo
scientif
ad
protein
incub
overnight
afterward
five
round
select
use
phagedisplay
ubv
librari
perform
immobil
protein
includ
follow
step
phage
particl
librari
pool
display
uniqu
ubv
encapsul
encod
dna
b
bind
phage
captur
immobil
protein
c
nonbind
phage
wash
away
bound
phage
amplifi
infect
bacteria
enrich
phage
pool
cycl
addit
round
select
enrich
proteinbind
ubv
fifth
round
bind
select
individu
phage
improv
bind
properti
identifi
phage
elisa
use
establish
techniqu
subject
dna
sequenc
phagemid
obtain
ubv
sequenc
merscov
pl
pro
complex
form
noncoval
merscov
pl
pro
ubv
complex
molar
excess
incub
merscov
pl
pro
overnight
excess
unbound
ubv
remov
sampl
use
superdex
size
exclus
column
fraction
contain
merscov
pl
pro
ubv
complex
pool
concentr
mgml
merscov
pl
pro
complex
found
crystal
similar
condit
previous
report
merscov
pl
pro
ub
complex
optim
crystal
appear
trisodium
citrat
ph
wv
polyethylen
glycol
peg
vv
isopropanol
crystal
merscov
pl
pro
complex
grown
trisodium
citrat
ph
wv
peg
vv
crystal
grown
mix
pl
pro
ubv
mgml
mgml
pl
pro
pl
pro
respect
crystal
solut
volumetr
ratio
merscov
pl
pro
ubv
well
solut
immedi
prior
mix
dtt
ad
merscov
pl
pro
ubv
complex
final
concentr
mm
prevent
oxid
sampl
purifi
cchfv
otu
pool
molar
excess
purifi
ubv
dialyz
overnight
mm
tri
ph
mm
nacl
mm
dtt
protein
complex
concentr
load
onto
superdex
size
exclus
column
elut
mm
tri
mm
nacl
mm
dtt
sampl
singl
peak
correspond
respect
complex
observ
gel
filtrat
profil
two
band
correspond
cchfv
otu
respect
ubv
observ
sdspage
indic
high
puriti
complex
cchfv
otu
complex
concentr
mgml
crystal
trial
initi
crystal
crystallin
materi
obtain
preliminari
screen
use
prepar
seed
stock
microse
matrix
screen
set
hang
drop
vapor
diffus
method
vdx
plate
hampton
research
carri
use
convent
screen
qiagen
without
heterogen
nucleat
use
cm
strand
human
hair
total
drop
volum
contain
equal
volum
protein
complex
well
solut
crystal
cchfv
otu
complex
grown
wv
peg
cacl
hepe
ph
appear
day
cchfv
otu
complex
concentr
mgml
initi
lead
observ
combinatori
approach
use
microse
matrix
screen
crystal
screen
qiagen
along
silver
bullet
screen
hampton
research
microseed
use
crystal
cchfv
otu
weaker
bind
variant
select
phage
display
complex
use
hang
drop
vapor
diffus
method
vdx
tray
hampton
research
screen
set
reservoir
volum
drop
size
compris
protein
complex
reservoir
solut
silver
bullet
addit
ad
order
crystal
obtain
wv
peg
tri
ph
sodium
chlorid
silver
bullet
formul
drop
follow
wv
acid
dehydr
dodecanedio
acid
hippur
acid
mellit
acid
oxalacet
acid
suber
acid
hepe
sodium
ph
data
collect
procedur
describ
support
inform
produc
lentivirus
cell
virgin
lab
washington
univers
school
medicin
grown
flask
transfect
packag
vector
pmdlgprre
prsvrev
envelop
proteinexpress
vector
pcmvvsvg
transfer
vector
contain
gfp
flagubv
use
polyethylenimin
pei
polysci
inc
medium
replac
h
post
transfect
h
h
post
transfect
supernat
collect
centrifug
x
g
min
filter
filter
storag
titer
lentiviru
particl
determin
antigen
elisa
zeptometrix
bartenschlag
lab
heidelberg
univers
cell
american
type
cultur
collect
grown
plate
transduc
lentivirus
encod
gfp
dilut
dmem
contain
fc
polybren
sigma
aldrich
medium
replac
h
post
transduct
pt
h
h
pt
protein
lysat
obtain
ad
contain
mm
nem
well
cell
grown
coverslip
fix
paraformaldehyd
pfa
pb
gfp
express
analyz
western
blot
describ
support
inform
fix
cell
grown
coverslip
permeabil
triton
pb
subsequ
indirect
immunofluoresc
assay
carri
primari
secondari
antibodi
dilut
pb
contain
fc
hoechst
ad
secondari
antibodi
dilut
stain
nuclear
dna
coverslip
analyz
zeiss
axioskop
fluoresc
microscop
axiocam
hrc
camera
obtain
cell
popul
cell
express
gfp
amount
lentiviru
yield
ng
requir
transduc
cell
ng
cell
requir
cell
transduc
lentivirus
encod
gfp
flagubaa
cell
infect
merscov
multipl
infect
h
h
pt
merscov
inocula
prepar
pb
contain
deaedextran
fc
cell
inocul
h
inoculum
replac
emem
contain
fc
supernat
harvest
h
post
merscov
infect
simultan
cell
lyse
lsb
western
blot
analysi
merscov
titer
determin
plaqu
assay
vero
cell
depart
virosci
erasmu
medic
center
describ
van
den
worm
et
al
merscov
infect
experi
perform
least
twice
plaqu
assay
perform
duplic
order
determin
merscov
titer
work
merscov
perform
insid
biosafeti
cabinet
biosafeti
level
facil
leiden
univers
medic
center
full
detail
materi
method
describ
supplement
file
appendix
coordin
file
structur
factor
deposit
protein
data
bank
access
code
merscov
pl
pro
structur
respect
cchfv
otucc
valu
determin
concentr
ubv
reduc
deubiquitin
deisgyl
activ
tabl
wt
ub
data
obtain
deisgyl
assay
fit
graphpad
prism
line
shown
residu
shown
sphere
sarscov
pl
pro
residu
indic
asterisk
ital
sarscov
pl
pro
residu
clash
residu
compar
ub
residu
c
sarscov
pl
pro
residu
clash
residu
respect
compar
ubwt
residu
e
rel
express
gfp
quantifi
normal
actin
express
level
cell
h
pt
set
c
gfp
transduc
cell
fix
h
h
pt
nuclear
dna
stain
use
hoechst
imag
taken
use
fix
exposur
time
gfp
hoechst
signal
immunofluoresc
assay
cell
fix
h
h
pt
cell
label
mous
monoclon
antibodi
recogn
flag
follow
label
secondari
goat
antimous
antibodi
exposur
time
kept
imag
